Japan Tobacco completes pharmaceutical business transfer to Shionogi

Japan Tobacco Inc. (JT) announced today, December 1, 2025, the successful completion of its pharmaceutical business transfer to Shionogi & Co., Ltd. The transfer was executed via a company simplified absorption-type split.

This completion follows previous disclosures, including the "Notice regarding the transfer of JT Group's Pharmaceutical Business through a company simplified absorption-type split," issued on May 7, 2025. Additionally, the "Notice Regarding the Conclusion of an Absorption-Type Split Contract Related to the Transfer of JT Group's Pharmaceutical Business to Shionogi & Co., Ltd. Through a Company Simplified Absorption-Type Split" was announced on September 25, 2025.

The transaction involved the succession of JT's pharmaceutical operations to Shionogi, as outlined in the absorption-type split contract.